Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18677709 | Data Transfer Mechanism between medical devices for medical data governance | May 2024 | May 2025 | Abandon | 12 | 2 | 0 | Yes | No |
| 17888035 | Risk Score and Classification System for Prevention of Complications in Plastic Surgery | August 2022 | February 2025 | Abandon | 30 | 1 | 0 | Yes | No |
| 17851839 | SYSTEM AND METHOD FOR PRESCRIBING DRUGS BASED ON A PATIENT'S INSURANCE PROVIDER | June 2022 | December 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17761285 | REHABILITATION PLANNING APPARATUS, REHABILITATION PLANNING SYSTEM, REHABILITATION PLANNING METHOD, AND COMPUTER READABLE MEDIUM | March 2022 | January 2025 | Abandon | 34 | 1 | 0 | No | No |
| 17634583 | AUTOMATED CONTINUOUS INSTRUMENT TRACKING SYSTEM | February 2022 | May 2025 | Allow | 39 | 2 | 0 | No | No |
| 17632928 | CONDITION PREDICTING APPARATUS, CONDITION PREDICTING METHOD, COMPUTER PROGRAM, AND RECORDING MEDIUM | February 2022 | May 2025 | Abandon | 39 | 2 | 0 | No | No |
| 17522755 | Methods, Systems, and Devices for Facilitating a Health Protection Protocol | November 2021 | October 2024 | Abandon | 35 | 1 | 0 | No | No |
| 17486251 | TELEHEALTH PROVIDER MANAGEMENT SYSTEM AND METHOD | September 2021 | October 2024 | Abandon | 36 | 1 | 0 | No | No |
| 17482037 | CUSTOMIZED MEDICAL TREATMENT | September 2021 | October 2024 | Abandon | 36 | 1 | 0 | No | No |
| 17464785 | METHOD FOR EVALUATING NUTRIENT CONTENT ON A CALORIE-SCALED BASIS | September 2021 | October 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17409192 | SYSTEMS AND METHODS FOR INCREASING PRIOR AUTHORIZATION SUCCESS RATE FOR SPECIALTY DRUGS | August 2021 | January 2025 | Abandon | 41 | 2 | 0 | Yes | No |
| 17364414 | SYSTEM AND METHODS FOR DETERMINING SCORES INDICATIVE OF A TRANSPLANT RECIPIENT'S ACTIVITIES AND BEHAVIORS | June 2021 | May 2025 | Abandon | 47 | 3 | 0 | Yes | No |
| 17362898 | EMERGENCY ROOM KIOSK FOR FINANCIAL ASSISTANCE AND INFORMATION | June 2021 | February 2025 | Abandon | 43 | 2 | 0 | No | No |
| 17226021 | SYSTEM FOR ASSESSING AND MITIGATING POTENTIAL SPREAD OF INFECTIOUS DISEASE AMONG DIALYSIS PATIENTS | April 2021 | October 2024 | Allow | 42 | 3 | 0 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner AMACHER, AUSTIN RIVOIRE works in Art Unit 3682 and has examined 8 patent applications in our dataset. With an allowance rate of 12.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.
Examiner AMACHER, AUSTIN RIVOIRE's allowance rate of 12.5% places them in the 1% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by AMACHER, AUSTIN RIVOIRE receive 1.75 office actions before reaching final disposition. This places the examiner in the 38% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by AMACHER, AUSTIN RIVOIRE is 41 months. This places the examiner in the 22% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +33.3% benefit to allowance rate for applications examined by AMACHER, AUSTIN RIVOIRE. This interview benefit is in the 81% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 25.0% of applications are subsequently allowed. This success rate is in the 39% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 0.0% of cases where such amendments are filed. This entry rate is in the 3% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 40% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 43% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.